Radius Stock Rides Rollercoaster After ASBMR Bone Data
This article was originally published in Scrip
Radius Health Inc. continues to report positive results for its osteoporosis therapy abaloparatide, but the company's stock has been on a somewhat bumpy ride since results were presented at the recent American Society of Bone and Mineral Research (ASBMR) meeting.
You may also be interested in...
Flagship Ventures Tempts Former Merck CMO With 'Creative' Mentoring Role
Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.
Finance Watch: Another VC Mega-Round As Flare Raises $123m Series B
Private Company Edition: Flare Therapeutics, targeting transcription factors to discover precision medicines, had big pharma backing for its second venture capital financing. Also, Mediar closed a $10m series A round, Switch launched with $52m and EpiBiologics raised a $50m series A round.
AbbVie’s Skyrizi Checks One Last Box With Phase III Success In Ulcerative Colitis
Already approved in Crohn’s disease, Skyrizi now has positive Phase III results in ulcerative colitis with more data expected this year in UC as the field grows more crowded with anti-IL-23 options.